The recent conference, `Alpha 1-antitrypsin deficiency and other conformational diseases', held in Airlie, Virginia, USA (27–30 June, 2000) focused on some of the common pathways by which cells ...

A slew of pharma mergers and acquisitions in the first month of 2024 has continued with a $2.2 billion play by Sanofi for Inhibrx and its clinical-stage drug candidate for alpha-1 antitrypsin ...

People with Pi*ZZ AATD do not naturally produce wild-type alpha-1 antitrypsin (M-AAT) protein. Thus, detecting the M-AAT protein confirms that mutant Z-AAT mRNA has been successfully edited.

The following is a summary of “Higher healthcare cost and utilization before and after diagnosis of AATD in the United States ...

KB408 for the treatment of alpha-1 antitrypsin deficiency (AATD) lung disease In September, after initiating dosing in Cohort 2, the Company amended the protocol for its KB408 Phase 1 SERPENTINE-1 ...

Korro Bio (KRRO) announced that it has received approval from the Australian Bellberry Human Research Ethics Committee, HREC, and clearance ...